Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 4/20 | 0.94 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL3657 | 0.97 | CA4 (1.00) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL11060179 | 0.97 | CA4 (1.00) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL715802 | 0.97 | CA4 (1.00) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL2235356 | 0.97 | CA4 (1.00) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL276988 | 0.97 | CA4 (1.00) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL28074297 | 0.95 | CA4 (0.85) | CA4CASP1 | |
| Citric Acid SCHEMBL25212993 | 0.94 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL5966797 | 0.94 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL3775695 | 0.94 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL20917176 | 0.94 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6468560-B2 | NERVOUS SYSTEM DISORDERS; ALZHEIMER'S DISEASE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-10-22 | — | — | US | claimed |
| WO-2024212009-A1 | SENSORS FOR DETECTING TARGET NUCLEIC ACIDS AND THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-10-17 | — | — | WO | disclosed |
| US-11806419-B2 | Aptamers for odor control applications | THE PROCTER & GAMBLE COMPANY (US) | 2023-11-07 | — | — | US | disclosed |
| EP-3956451-A1 | APTAMERS FOR ODOR CONTROL APPLICATIONS | The Procter & Gamble Company (US) | 2022-02-23 | — | — | EP | disclosed |
| US-7309584-B2 | Mutations of the MDR1 P-glycoprotein that improves its ability to confer resistance to chemotherapeutic drugs | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-12-18 | — | — | US | disclosed |
| US-20060093689-A1 | Skin cosmetics | TAKASAGO INTERNATIONAL CORPORATION | 2006-05-04 | — | — | US | disclosed |
| EP-1428523-A1 | Skin cosmetics | Takasago International Corporation (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-20040086882-A1 | Mutations of the mdr1 p-glycoprotein that improves its ability to confer resistance to chemotherapeutic drugs | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-05-06 | — | — | US | disclosed |
| US-20030104495-A1 | Sperm-specific AKAP protein genes and uses | CARR DANIEL W (US) | 2003-06-05 | — | — | US | disclosed |
| US-6451528-B1 | ISOLATED NUCLEIC ACID ENCODING SPERM-SPECIFIC PROTEIN KINASE A ANCHORING PROTEINS FROM MAMMALIAN SPECIES, RECOMBINANT EXPRESSION CONSTRUCTS ENCODING SAID MAMMALIAN SPERM-SPECIFIC PROTEIN KINASE A ANCHORING PROTEINS, CELLS TRANSFORMED WITH | OREGON HEALTH & SCIENCES UNIVERSITY | 2002-09-17 | — | — | US | disclosed |
| WO-2002010205-A2 | MUTATIONS OF THE MDR1 P-GLYCOPROTEIN THAT IMPROVE ITS ABILITY TO CONFER RESISTANCE TO CHEMOTHERAPEUTIC DRUGS | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2002-02-07 | — | — | WO | disclosed |
| US-5849499-A | Monoclonal antibody to acetylated lysine residues in recombinant bovine somatotropin | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0754966-A1 | Silver halide light-sensitive photographic material and processing method thereof | KONICA CORPORATION (JP) | 1997-01-22 | — | — | EP | disclosed |
| EP-0485525-B1 | MONOCLONAL ANTIBODY TO ACETYLATED LYSINE RESIDUES IN RECOMBINANT BOVINE SOMATOTROPIN | UPJOHN CO (US) | 1994-09-14 | — | — | EP | disclosed |
| EP-0485525-A1 | MONOCLONAL ANTIBODY TO ACETYLATED LYSINE RESIDUES IN RECOMBINANT BOVINE SOMATOTROPIN. | UPJOHN CO (US) | 1992-05-20 | — | — | EP | disclosed |
| WO-1991002080-A2 | MONOCLONAL ANTIBODY TO ACETYLATED LYSINE RESIDUES IN RECOMBINANT BOVINE SOMATOTROPIN | THE UPJOHN COMPANY (US) | 1991-02-21 | — | — | WO | disclosed |
| US-4585530-A | Process for forming adherent chromium electrodeposits from high energy efficient bath on ferrous metal substrates | M&T CHEMICALS INC. (US) | 1986-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11806419-B2 | Aptamers for odor control applications | TAS2R40, TAS2R10, OR10J3 | CA4 1313/4885CASP1 4188/4885FFAR3 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.